Titan Pharmaceuticals — Investor Presentation (June 2016)
23 slides from Titan Pharmaceuticals's investor presentation, Jun 20, 2016
Slide 1: Titan Pharmaceuticals Corporate Presentation
TITAN PHARMACEUTICALS CORPORATE PRESENTATION SUNIL BHONSLE JUNE 2016 © 2016 TITAN PHARMACEUTICALS INC. NASDAQ:TTNP
Slide 2: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS The presentation may contain “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Reference is made in particular to the description of our plans and objectives for futur
Slide 3: Company Snapshot
COMPANY SNAPSHOT 3 • Focus on proprietary therapeutics for select chronic diseases • ProNeura TM drug delivery platform provides long - term, continuous, non - fluctuating medication levels • Probuphine® (buprenorphine) implant – six - month maintenance treatment of opioid addiction • FDA approval M
Slide 4: Opioid Addiction: An Epidemic
OPIOID ADDICTION: AN EPIDEMIC • Increasingly recognized as a global epidemic by world health authorities • Primary, chronic disease of brain reward, motivation, memory and neurobiological circuitry • Characterized by cravings, accompanied by a lack of impulse control, cycles of relapse and remission
Slide 5: Opioid Addiction: Treatment Overview
OPIOID ADDICTION: TREATMENT OVERVIEW 5 • Buprenorphine pharmacology makes it an effective, safer, and more convenient treatment option • Controls withdrawal symptoms and cravings without inducing opioid euphoria in patients • Convenient outpatient treatment allows take - home medication, unlike meth
Slide 6: Probuphine (Buprenorphine) Implant
PROBUPHINE® (BUPRENORPHINE) IMPLANT 6 • Implant contains 80 mg of buprenorphine HCl uniformly distributed throughout the ethylene vinyl acetate co - polymer (EVA) matrix • No reservoir, therefore no risk of drug dumping EVA POLYMER BUPRENORPHINE PROBUPHINE BLENDED & EXTRUDED
Slide 7: Probuphine Administration
PROBUPHINE® ADMINISTRATION 7 • Inserted subdermally in the inner side of the upper arm by a certified health care provider • Drug is released continuously into patient's body through the process of dissolution • Results in a stable level of medication in the blood, avoiding peaks and troughs of oral
Slide 8: Probuphine (Buprenorphine) Implant
PROBUPHINE® (BUPRENORPHINE) IMPLANT 8 Probuphine® is the first and only FDA - approved maintenance treatment for opioid dependence that provides non - fluctuating blood levels of buprenorphine around - the - clock for a period of six months EFFICACY Effective in reducing illicit opioid use SAFETY No
Slide 9: Probuphine: Commercialization Plans
PROBUPHINE®: COMMERCIALIZATION PLANS 9 Partnership with Braeburn Pharmaceuticals, Inc. for development and commercialization in U.S. and Canada* • Milestone payments: • Upfront : $15.75 million • Approval Milestone: $15 million • Sales Milestones: $165 million • Tiered Royalties on net sales: mid -
Slide 10: Probuphine: Risk Evaluation & Mitigation Strategy
PROBUPHINE®: RISK EVALUATION & MITIGATION STRATEGY 10
Slide 11: Probuphine: Risk Evaluation & Mitigation Strategy
PROBUPHINE®: RISK EVALUATION & MITIGATION STRATEGY 11 • Training and Certification – Providers who prescribe and implant Probuphine will: • A ttend Live Training: Lecture and Practicum • C omplete the Probuphine REMS P rogram K nowledge Assessment • B e enrolled in the Probuphine REMS program • Prov
Slide 12: Probuphine: U.S. Certified Health Care Providers
PROBUPHINE®: U.S. CERTIFIED HEALTH CARE PROVIDERS 12
Slide 13: Probuphine: Ex-U.S. Partnering Plans
PROBUPHINE®: EX - U.S. PARTNERING PLANS 13 • Pursuing ex - U.S. opportunities in opioid addiction treatment • Progressing discussions with interested companies in select regions • Planning regulatory discussions with EMA and/or select European countries in second half of 2016 • Opportunity to furthe
Slide 14: ProNeura: Adding Value Beyond Probuphine
PRONEURA: ADDING VALUE BEYOND PROBUPHINE® 14 • Long - term drug delivery technology validated through the Probuphine® program • Potential for the treatment of select chronic diseases for which low dose, long - term delivery and stable drug levels may offer advantages over other forms of administrati
Slide 15: Parkinson's Disease Overview
PARKINSON’S DISEASE OVERVIEW • Characterized by the loss of dopamine, which alters activity in the brain region impacting movement and motor function • Treated with drugs designed to replace or mimic dopamine in the brain • After several years of treatment , these drugs lose benefit and trigger seri
Slide 16: Parkinson's Disease – Therapeutics Market
PARKINSON’S DISEASE – THERAPEUTICS MARKET 16 * GlobalData; **Parkinson’s Action Network, National Center for Health Statistics; “The Current and Projected Economic Burden of Parkinson’s Disease in the United States” Movement Disorders, March 2013 Based on information from Titan and other sources bel
Slide 17: ProNeura Parkinson's Disease Program
PRONEURA TM PARKINSON’S DISEASE PROGRAM 17 • Ropinirole (Requip®), a dopamine agonist marketed by GSK for PD • Evaluated in a Parkinsonian animal model using ProNeura T M drug delivery platform • Results presented in June 2015 - 19th International Congress of Parkinson's Disease and Movement Disorde
Slide 18: Hypothyroidism Disease Overview
HYPOTHYROIDISM DISEASE OVERVIEW • Thyroid gland does not make enough thyroid hormone to meet body’s need • Typical treatment consists of synthetic prohormone thyroxine (T4) given orally once a day, which is converted by the body to the active triiodothyronine (T3) • Oral T3 treatment is effective, b
Slide 19: ProNeura Hypothyroidism Program Status
PRONEURA TM HYPOTHYROIDISM PROGRAM STATUS 19 • Completed initial formulation development of the implant and conducted in - vitro and in - vivo drug release studies to further define implant formulation • In - vivo non - clinical studies in progress evaluating implant formulations for drug release ch
Slide 20: Titan ProNeura Product Pipeline
TITAN PRONEURA PRODUCT PIPELINE 20 CANDIDATE INDICATION DEVELOPMENT STAGE Probuphine ® Opioid Addiction Ropinirole Implant Parkinson’s Disease T3 Implant Hypothyroidism PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET
Slide 21: Titan Executive Management
TITAN EXECUTIVE MANAGEMENT 21 • Marc Rubin, M . D . Executive Chairman & Director • 9 years with Titan • Former Head of Global R&D and member of the Board of Management at Bayer Pharma • Executive R&D and commercial responsibilities at GSK for 13 years • 25 years in the pharmaceutical industry follo
Slide 22: Titan Pharma Summary
TITAN PHARMA SUMMARY • ProNeura ™ - Unique and compelling drug delivery platform • Probuphine ® - Only product on market to provide long - term, continuous, non - fluctuating blood levels of buprenorphine for maintenance treatment of opioid addiction • Attractive U . S . partnership in place and pur
Slide 23: Thank You. Questions?
THANK YOU. QUESTIONS? © 2016 TITAN PHARMACEUTICALS INC. NASDAQ:TTNP
Titan Pharmaceuticals — Investor Presentation (June 2016) on 6ix